论文部分内容阅读
芦氟沙星（ｒｕｆｌｏｘａｃｉｎ）是一种新型氟喹诺酮类广谱抗菌药物。为评价其安全有效性，以氧氟沙星为对照药，采用随机对照临床试验的方法治疗呼吸道感染６４例。剂量用法：芦氟沙星，口服，第一日用量４００ｍｇ，ｑｄ，第二日至疗程结束用量２００ｍｇｑｄ；氧氟沙星，３００ｍｇ，ｂｉｄ。程疗均为７～９ｄ。芦氟沙星与氧氟沙星临床疗效评价病例数分别为３３例与３１例，两药临床有效率分别为８７．９％与９３．５％，治疗各种细菌感染的有效率分别为８６．７％与９２．３％，细菌学诊断阳性率分别为９０．９％和８３．９％，细菌清除率分别为８６．７％与９２．３％，药物不良反应发生率分别为９．１％与９．７％。以上结果经统计学处理均无显著差异（Ｐ＞０．０５）。
Rufloxacin is a novel fluoroquinolone broad-spectrum antibacterial. To evaluate its safety and efficacy, ofloxacin as a control drug, a randomized controlled clinical trial of 64 cases of respiratory tract infections. Dosage usage: Lufloxacin, oral, the first daily dose of 400mg, qd, the second day to the end of the dose of 200mgqd; Ofloxacin, 300mg, bid. Cheng treatment are 7 ~ 9d. The clinical efficacy of rufloxacin and ofloxacin were evaluated in 33 and 31 cases respectively. The effective rates of the two drugs were 87.9% and 93.5%, respectively. The effective rates of treating various bacterial infections were 86 .7% and 92.3% respectively. The positive rate of bacteriological diagnosis was 90.9% and 83.9% respectively. The bacterial clearance rate was 86.7% and 92.3% respectively. The incidence of adverse drug reactions was 9. 1% and 9.7%. The above results by statistical analysis showed no significant difference (P> 0.05).